N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10927129
APP PUB NO 20190284208A1
SERIAL NO

16400373

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
VIIV HEALTHCARE COMPANY251 LITTLE FALLS DRIVE WILMINGTON DE 19808

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Johns, Brian A Research Triangle Park, US 56 338
Kawasuji, Takashi Osaka, JP 45 683
Taishi, Teruhiko Osaka, JP 28 399
Taoda, Yoshiyuki Osaka, JP 58 784

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 23, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 23, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00